

Performance In Delivering - Q2: 2017/2018 (1st October 2016 - 30th September 2017) - HRA studies

Research Ethics Committee Reference Number	IRAS number	Name of Trial	Target number of patients	Date Agreed to recruit target number of patients	Number of patients recruited by agreed date	Closed to Recruitment date	Reason for Closure
14/LO/0727	153790	ITIND: Study to assess the efficacy of Medi-tate TIND in BPH	6	31/12/2016	7	31/12/2016	End of Recruitment
16/LO/1001	199167	A randomized, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual impairment due to center-involved diabetic macular edema (DME)	2	30/09/2017	3	22/06/2017	End of Recruitment
16/WA/0046	188274	A Multi-Center, Open-Label, Single-Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency	1	30/04/2017	0	30/03/2017	Target was reached earlier than expected
15/SC/0409	183061	Sequoia: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration	8	30/05/2017	6	30/03/2017	End of Recruitment

15/EM/0437	184390	Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD)	6	09/06/2017	3	09/06/2017	End of Recruitment
17/SC/0022	215467	Panorama: A phase 3 double-masked randomised study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe nonproliferative diabetic retinopathy	3	30/09/2017	1	07/08/2017	End of Recruitment